Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Discovery and structure-activity relationships of small molecules that block the human immunoglobulin G-human neonatal Fc receptor (hIgG-hFcRn) protein-protein interaction.

Wang Z, Fraley C, Mezo AR.

Bioorg Med Chem Lett. 2013 Mar 1;23(5):1253-6. doi: 10.1016/j.bmcl.2013.01.014. Epub 2013 Jan 11.

PMID:
23375228
2.

Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn.

Mezo AR, McDonnell KA, Hehir CA, Low SC, Palombella VJ, Stattel JM, Kamphaus GD, Fraley C, Zhang Y, Dumont JA, Bitonti AJ.

Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2337-42. doi: 10.1073/pnas.0708960105. Epub 2008 Feb 12.

3.

Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics.

Mathur A, Arora T, Liu L, Crouse-Zeineddini J, Mukku V.

J Immunol Methods. 2013 Apr 30;390(1-2):81-91. doi: 10.1016/j.jim.2013.01.011. Epub 2013 Feb 4.

PMID:
23384837
4.

Structure-activity relationships of a peptide inhibitor of the human FcRn:human IgG interaction.

Mezo AR, McDonnell KA, Castro A, Fraley C.

Bioorg Med Chem. 2008 Jun 15;16(12):6394-405. doi: 10.1016/j.bmc.2008.05.004. Epub 2008 May 6.

PMID:
18501614
5.

Synthesis and structure-activity relationships of dimeric peptide antagonists of the human immunoglobulin G-human neonatal Fc receptor (IgG-FcRn) interaction.

McDonnell KA, Low SC, Hoehn T, Donnelly R, Palmieri H, Fraley C, Sakorafas P, Mezo AR.

J Med Chem. 2010 Feb 25;53(4):1587-96. doi: 10.1021/jm901128z.

PMID:
20092334
6.

Contribution of FcRn binding to intestinal uptake of IgG in suckling rat pups and human FcRn-transgenic mice.

Kliwinski C, Cooper PR, Perkinson R, Mabus JR, Tam SH, Wilkinson TM, Giles-Komar J, Scallon B, Powers GD, Hornby PJ.

Am J Physiol Gastrointest Liver Physiol. 2013 Feb 1;304(3):G262-70. doi: 10.1152/ajpgi.00340.2012. Epub 2012 Dec 6.

7.

A strategy for bacterial production of a soluble functional human neonatal Fc receptor.

Andersen JT, Justesen S, Berntzen G, Michaelsen TE, Lauvrak V, Fleckenstein B, Buus S, Sandlie I.

J Immunol Methods. 2008 Feb 29;331(1-2):39-49. Epub 2007 Dec 10.

PMID:
18155020
8.

Neonatal Fc receptor and IgG-based therapeutics.

Kuo TT, Aveson VG.

MAbs. 2011 Sep-Oct;3(5):422-30. doi: 10.4161/mabs.3.5.16983. Epub 2011 Sep 1. Review.

9.

Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.

Wang Y, Tian Z, Thirumalai D, Zhang X.

J Drug Target. 2014 May;22(4):269-78. doi: 10.3109/1061186X.2013.875030. Epub 2014 Jan 9. Review.

PMID:
24404896
10.

Inhibitors of the FcRn:IgG protein-protein interaction.

Low SC, Mezo AR.

AAPS J. 2009 Sep;11(3):432-4. doi: 10.1208/s12248-009-9120-5. Epub 2009 Jun 5. Review.

11.

Field flow fractionation for assessing neonatal Fc receptor and Fcγ receptor binding to monoclonal antibodies in solution.

Pollastrini J, Dillon TM, Bondarenko P, Chou RY.

Anal Biochem. 2011 Jul 1;414(1):88-98. doi: 10.1016/j.ab.2011.03.001. Epub 2011 Mar 6.

PMID:
21385563
12.

Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.

Petkova SB, Akilesh S, Sproule TJ, Christianson GJ, Al Khabbaz H, Brown AC, Presta LG, Meng YG, Roopenian DC.

Int Immunol. 2006 Dec;18(12):1759-69. Epub 2006 Oct 31.

PMID:
17077181
13.

The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity.

Abdiche YN, Yeung YA, Chaparro-Riggers J, Barman I, Strop P, Chin SM, Pham A, Bolton G, McDonough D, Lindquist K, Pons J, Rajpal A.

MAbs. 2015;7(2):331-43. doi: 10.1080/19420862.2015.1008353.

14.
15.

The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases.

Sesarman A, Vidarsson G, Sitaru C.

Cell Mol Life Sci. 2010 Aug;67(15):2533-50. doi: 10.1007/s00018-010-0318-6. Epub 2010 Mar 9. Review.

PMID:
20217455
16.

Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn.

Kim JK, Firan M, Radu CG, Kim CH, Ghetie V, Ward ES.

Eur J Immunol. 1999 Sep;29(9):2819-25.

17.

FcRn: the neonatal Fc receptor comes of age.

Roopenian DC, Akilesh S.

Nat Rev Immunol. 2007 Sep;7(9):715-25. Epub 2007 Aug 17. Review.

PMID:
17703228
18.

Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?

Gurbaxani B, Dostalek M, Gardner I.

Mol Immunol. 2013 Dec;56(4):660-74. doi: 10.1016/j.molimm.2013.05.008. Epub 2013 Aug 2. Review.

PMID:
23917469
19.

The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy.

Sockolosky JT, Szoka FC.

Adv Drug Deliv Rev. 2015 Aug 30;91:109-24. doi: 10.1016/j.addr.2015.02.005. Epub 2015 Feb 19. Review.

20.

Selection of nanobodies that target human neonatal Fc receptor.

Andersen JT, Gonzalez-Pajuelo M, Foss S, Landsverk OJ, Pinto D, Szyroki A, de Haard HJ, Saunders M, Vanlandschoot P, Sandlie I.

Sci Rep. 2013;3:1118. doi: 10.1038/srep01118. Epub 2013 Jan 23.

Supplemental Content

Support Center